BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38566874)

  • 1. Role of Calprotectin, IL-6, and CRP in Distinguishing Between Inflammatory Bowel Disease and Diarrhea Predominant Irritable Bowel Syndrome.
    Huong BT; Hien NM; Dung NT; Quang DM; Vinh NT; Tu TT; Chi TK; Phuong LB; Nhan NT
    Med Arch; 2024; 78(2):105-111. PubMed ID: 38566874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
    Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
    Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ
    J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
    Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
    World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Performance of a Novel LIAISON Fecal Calprotectin Assay for Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome.
    Campbell JP; Zierold C; Rode AM; Blocki FA; Vaughn BP
    J Clin Gastroenterol; 2021 Mar; 55(3):239-243. PubMed ID: 32324678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
    Diederen K; Hoekman DR; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Vlieger AM; Kindermann A; Benninga MA
    Aliment Pharmacol Ther; 2016 Jul; 44(2):181-8. PubMed ID: 27110920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies.
    Schoepfer AM; Trummler M; Seeholzer P; Seibold-Schmid B; Seibold F
    Inflamm Bowel Dis; 2008 Jan; 14(1):32-9. PubMed ID: 17924558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
    Oyaert M; Trouvé C; Baert F; De Smet D; Langlois M; Vanpoucke H
    Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
    Sydora MJ; Sydora BC; Fedorak RN
    J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered fecal bile acid composition in active ulcerative colitis.
    Sommersberger S; Gunawan S; Elger T; Fererberger T; Loibl J; Huss M; Kandulski A; Krautbauer S; Müller M; Liebisch G; Buechler C; Tews HC
    Lipids Health Dis; 2023 Nov; 22(1):199. PubMed ID: 37980492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
    Shimoyama T; Yamamoto T; Yoshiyama S; Nishikawa R; Umegae S
    Inflamm Bowel Dis; 2023 Sep; 29(9):1399-1408. PubMed ID: 36334015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Level of interleukin 17 in inflammatory bowel disease and its relation with disease activity.
    Menesy A; Hammad M; Aref S; Abozeid FAM
    BMC Gastroenterol; 2024 Apr; 24(1):135. PubMed ID: 38622545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulcerative colitis, Crohn's disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn's disease.
    Mortensen JH; Manon-Jensen T; Jensen MD; Hägglund P; Klinge LG; Kjeldsen J; Krag A; Karsdal MA; Bay-Jensen AC
    PLoS One; 2017; 12(10):e0185855. PubMed ID: 29028807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Hoekman DR; Zeevenhooven J; D'Haens GR; Benninga MA
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
    Mori A; Mitsuyama K; Sakemi R; Yoshioka S; Fukunaga S; Kuwaki K; Yamauchi R; Araki T; Yoshimura T; Yamasaki H; Tsuruta K; Morita T; Yamasaki S; Tsuruta O; Torimura T
    Kurume Med J; 2021 Dec; 66(4):209-215. PubMed ID: 34690210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Manolakis AC; Kapsoritakis AN; Georgoulias P; Tzavara C; Valotassiou V; Kapsoritaki A; Potamianos SP
    BMC Gastroenterol; 2010 Oct; 10():118. PubMed ID: 20946669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
    Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
    Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.